Is DaVita (DVA) overvalued or fairly valued?

MarketChacha shows DaVita's valuation in context — a trailing P/E of about 16.0, a forward P/E of about 10.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does DaVita's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (2.51×) from reported figures — education, not a rating.

What is DaVita's revenue?

DaVita reported revenue of $13.6B for FY2025, with net profit of $746.8M, per official filings.

What is the share price of DaVita (DVA)?

DaVita last traded at $183.99 (+1.3% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

DaVita

DVA · NYSE · Healthcare · United States

Snapshot

TickerDVA

ExchangeNYSE

SectorHealthcare

IndustryMedical Care Facilities

CountryUnited States

Employees78,000

HeadquartersDenver, United States

Websitewww.davita.com

Filings tracked13

About DaVita

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.

Who owns it

Insiders46.9%
Institutions49.2%
Public & other3.8%

868 institutional holders

Ownership breakdown from public market data.

Top holders

Berkshire Hathaway, Inc45.27%
Blackrock Inc.3.86%
Vanguard Capital Management LLC3.29%
Morgan Stanley2.51%
Vanguard Portfolio Management LLC2.16%
State Street Corporation2.07%
Invesco Ltd.1.90%
Dimensional Fund Advisors LP1.78%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion2.51×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend5.7% → 5.5%

Margin has held broadly steady over the period — stable profitability.

Return on equity773.1%

Latest ROE of 773.1% — capital is generating a healthy return.

Growth qualityrev 6% · PAT 4%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $3.6B · EPS 4.41

Est. earnings growth +29.8%

Next fiscal year

Rev $14.6B · EPS 17.25

Est. earnings growth +16.2%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$13.6B

Net margin

5.5%

Revenue CAGR (2y)

+6.0%

Profit CAGR (2y)

+3.9%

EPS (FY2025)

9.84

Net profit (FY2025)

$746.8M

Ask MarketChacha about DVA

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$13.6B	$746.8M	9.84	5.5%	—
FY2024	$12.8B	$936.3M	10.73	7.3%	773.1%
FY2023	$12.1B	$691.5M	7.42	5.7%	65.5%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$3.6B	$265.4M	4.02	7.5%
2026Q1	$3.4B	$197.5M	2.87	5.8%
2025Q3	$3.4B	$150.3M	2.04	4.4%
2025Q2	$3.4B	$199.3M	2.58	5.9%
2025Q1	$3.2B	$162.9M	2.00	5.1%
2024Q3	$3.3B	$214.7M	2.50	6.6%
2024Q2	$3.2B	$222.7M	2.50	7.0%
2024Q1	$3.1B	$239.6M	2.65	7.8%
2023Q3	$3.1B	$246.6M	2.62	7.9%
2023Q2	$3.0B	$178.7M	1.91	6.0%
2023Q1	$2.9B	$115.5M	1.25	4.0%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Exhibits
SEC8/4/2026material
10-Q filing
SEC8/4/2026
8-K — Material agreement, Material financial obligation, Shareholder vote results, Exhibits
SEC6/8/2026material
8-K — Results of operations, Exhibits
SEC5/5/2026material
10-Q filing
SEC5/5/2026
10-K filing
SEC2/11/2026
8-K — Results of operations, Exhibits
SEC2/2/2026material

2025

8-K — Material agreement, Material financial obligation, Exhibits
SEC11/25/2025material
8-K — Results of operations, Exhibits
SEC10/29/2025material
10-Q filing
SEC10/29/2025
8-K — Other events
SEC8/20/2025material
8-K — Results of operations, Exhibits
SEC8/5/2025material
10-Q filing
SEC8/5/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.